A

    Alpha Tau Medical Ltd (DRTS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.03
    +0.41 (+2.80%)

    Market Cap: $1.33B

    Last updated: Sep 04, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(11/20)
    Avg Surprise
    -37.13%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.15 - $-0.13
    4 analysts
    EPS RevisionsNo revisions (7d)
    1
    3
    30d
    EPS Estimate Drift
    90d ago$-0.12+12.1%
    60d ago$-0.14+2.2%
    30d ago$-0.14+0.0%
    7d ago$-0.14+0.0%
    Current$-0.14
    Revenue Consensus
    $192670
    Range$0 - $378000
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.47
    Range$-0.67 - $-0.15
    5 analysts
    Revenue Consensus
    $181660
    Range$-479840 - $843160
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.47---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 10
    		$-0.50$-0.14-257.14%Miss-284.6%
    Mar 26
    Reported May 18
    		$-0.26$-0.12-116.67%Miss-116.7%
    Dec 25
    Reported Mar 9
    		$-0.14$-0.12-13.54%Miss-7.7%
    Sep 25
    Reported Nov 20
    		$-0.14$-0.12-16.67%Miss-40.0%
    Jun 25
    Reported Aug 11
    		$-0.13$-0.11-18.18%Miss-18.2%
    Mar 25
    Reported May 19
    		$-0.12$-0.14+14.29%Beat-9.1%
    Dec 24
    Reported Mar 12
    		$-0.13$-0.13+0.00%Beat-18.2%
    Sep 24
    Reported Nov 21
    		$-0.10$-0.12+16.67%Beat+60.0%
    Jun 24
    Reported Aug 14
    		$-0.11$-0.12+8.33%Beat+8.3%
    Mar 24
    Reported May 20
    		$-0.11$-0.13+15.38%Beat+8.3%
    Dec 23
    Reported Mar 7
    		$-0.11$-0.12+8.33%Beat-120.0%
    Sep 23
    Reported Nov 16
    		$-0.25$-0.12-108.33%Miss-525.0%
    Jun 23
    Reported Aug 28
    		$-0.12$-0.13+7.69%Beat-300.0%
    Mar 23
    Reported May 23
    		$-0.12$-0.11-9.09%Miss+77.8%
    Dec 22
    Reported Mar 9
    		$-0.05N/A+54.55%Beat+82.8%
    Sep 22
    Reported Nov 22
    		$-0.04N/A+66.67%Beat-500.0%
    Jun 22
    Reported Aug 25
    		$-0.03N/A+75.00%Beat+57.1%
    Mar 22
    Reported May 26
    		$-0.54$-0.08-575.00%Miss-334.8%
    Dec 21
    Reported Mar 28
    		$-0.29$-0.26-11.54%Miss-
    Sep 21
    Reported Nov 15
    		$0.01N/A+116.67%Beat-
    Jun 21
    Reported Aug 16
    		$-0.07N/AN/ABeat-
    Mar 21
    Reported May 28
    		$0.23N/AN/ABeat-
    Dec 20
    Reported Jan 13
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-14.45EV/EBITDA-4.77x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-141.70%ROIC-72.59%
    Financial Health
    Debt/Equity0.34xInterest CoverageN/A
    Current Ratio11.09xQuick Ratio11.09x
    Trading Statistics
    Beta1.19Avg Volume636.72K
    52-Week High$15.1052-Week Low$3.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$14.59
    SMA 20$14.43
    SMA 50$13.30
    SMA 200$8.78
    EMA 10$14.52
    EMA 20$14.23
    EMA 50$13.16
    EMA 200$9.50

    MACD

    Line: 0.45Signal: 0.52Hist: -0.06

    ADX

    ADX: 20.7+DI: 21.3-DI: 15.4

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$13.68

    Bollinger Bands

    Upper Band$15.19
    Lower Band$13.66
    %B Position1058%(Upper)
    Band Width0.90

    RSI (14-Day)

    Neutral
    62.6

    Momentum Oscillators

    Stoch %K68.2
    Stoch %D49.9
    Williams %R-9.2
    ROC (10d)0.7%
    Momentum0.11
    CCI (20d)103.7
    MFI (14d)44.9

    Volatility Measures

    ATR (14d)$0.69(4.6%)
    StdDev (20d)0.38
    Hist Vol39.6%(Moderate)

    Volume Flow

    VWAP$14.88
    OBV16.8M
    AD Line6.3M
    CMF (20d)-0.076

    Volume Metrics

    Avg Vol (20d)666.6K
    Vol Ratio1.1x
    VWMA (20d)$14.38

    Pivot Points

    R3$15.77
    R2$15.42
    R1$15.02
    Pivot Point$14.67
    S1$14.27
    S2$13.92
    S3$13.52

    Advanced Oscillators

    TSI19.74
    Ultimate Osc46.0
    KST129.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total RevenueN/A$0$0$0$0$0$0$0$0$0$0$0
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.07MN/A
    Gross ProfitN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A$-1,074,000N/A
    Operating Expenses$13.78M$13.31M$12.60M$10.73M$9.65M$9.31M$10.27M$8.29M$9.05M$8.42M$8.87M$8.93M
    R&D$9.91M$10.97M$9.58M$8.31M$7.01M$7.17M$7.53M$6.17M$6.87M$6.45M$7.49M$6.67M
    SG&A$3.56M$2.10M$2.57M$1.93M$2.18M$1.68M$2.05M$1.59M$1.59M$1.44M$2.00M$1.70M
    Operating Income$-13,782,000$-13,313,000$-12,602,000$-10,730,000$-9,648,000$-9,308,000$-10,274,000$-8,290,000$-9,054,000$-8,424,000$-9,943,000$-8,925,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$31.80M$9.64M$0$2.34M$401,000$0$0$0$0$0$0$2.03M
    Income Before Tax$-45,584,000$-22,950,000$-12,171,000$-11,694,000$-10,049,000$-8,592,000$-9,474,000$-6,924,000$-7,366,000$-7,980,000$-7,357,000$-4,951,000
    Income Tax Expense$229,000$-11,000$-35,000$-8,000$65,000$99,000$2,000$0$3,000$1,000$8,000$-39,000
    Net Income$-45,813,000$-22,939,000$-12,136,000$-11,686,000$-10,114,000$-8,691,000$-9,476,000$-6,924,000$-7,369,000$-7,981,000$-7,365,000$-4,912,000
    EBITDA$-13,782,000$-13,313,000$-11,241,000$-10,730,000$-9,177,000$-9,308,000$-5,397,500$-8,021,500$-8,774,000$-8,155,500$-8,869,000$-8,680,250
    EBITN/AN/A$-12,473,000$-11,476,500$-9,443,500$-9,583,500$-5,673,000$-8,290,000$-9,054,000$-8,424,000$-9,943,000$-8,925,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DRTS

    News

    H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment

    H.C. Wainwright maintained a Buy rating and a $16.00 price target for Alpha Tau Medical (NASDAQ:DRTS) after the company completed patient enrollment for its IMPACT pilot study. The study investigates the Alpha DaRT treatment in combination with chemotherapy for pancreatic adenocarcinoma, with topline data expected in early 2027. Despite a recent net loss, the company has seen previous positive developments, including FDA clearance for another trial and promising results for pancreatic cancer treatment.

    Investing.com•9/1/26•
    Bullish

    Alpha Tau Completes Enrollment in IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT

    Alpha Tau Medical has completed enrollment for its IMPACT pilot study, which investigates the combination of intratumoral Alpha DaRT with first-line chemotherapy for unresectable pancreatic cancer. The study enrolled 48 patients across 10 centers and will now proceed to follow-up, with initial data expected in early 2027 to inform future pivotal studies. Despite a "Neutral" rating from TipRanks' AI Analyst due to weak financial performance, the company aims to position Alpha DaRT as a targeted radiotherapy solution for solid malignancies.

    TipRanks•8/31/26•
    Somewhat-Bullish

    Price to book forward of Alpha Tau Medical Ltd. – NASDAQ:DRTSW

    This article provides the "Price to book forward" financial metric for Alpha Tau Medical Ltd. (NASDAQ: DRTSW). It indicates that the market was closed at the time of publication and there were no trades. The information is presented within the context of TradingView's platform, which offers various financial tools and market data.

    TradingView•8/24/26•
    Neutral

    Alpha Tau Medical (DRTS) officer schedules next stock sale under 10b5-1 plan

    An officer of Alpha Tau Medical (DRTS), Raphael (Raphi) Aryeh Levy, has filed a notice to sell 5,000 Ordinary Shares worth $71,800.00 under a Rule 10b5-1 trading plan adopted on March 24, 2026. The sale is scheduled for August 21, 2026, and is tied to the cash exercise of employee stock options. The filing also details Levy's previous Rule 144 sales in June, July, and August 2026, indicating ongoing insider transactions.

    Stock Titan•8/21/26•
    Neutral

    Alpha Tau Medical (NASDAQ:DRTS) Sets New 1-Year High - Here's What Happened

    Alpha Tau Medical (NASDAQ:DRTS) reached a new 52-week high of $14.79, trading at $14.75, up from its previous close of $14.36. Despite the stock performance, the company reported a wider-than-expected quarterly loss of $0.50 per share and lower-than-anticipated revenue of $0.10 million. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $12.80, though some firms have recently raised their targets to $16-$17.

    MarketBeat•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About DRTS

    Does DRTS pay dividends?
    Alpha Tau Medical Ltd (DRTS) does not currently pay a regular dividend.
    What is DRTS's market cap?
    Alpha Tau Medical Ltd (DRTS) has a market capitalization of $1.33B with a current stock price of $15.03.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In